Researchers reclassified 86 percent of variants initially determined to be VUS, potentially changing surveillance or treatment approaches for patients.
The companies have worked together on a number of other cancer-related projects, including a companion diagnostic for the ovarian cancer treatment olaparib.
The first-in-human clinical trial will evaluate XL102 as a treatment for patients with advanced solid tumors, including breast, ovarian, and prostate cancers.
The TuPro study will evaluate whether a comprehensive suite of routine and emerging tests can add value to treatment decision making and improve outcomes.
The Japanese Ministry of Health, Labor, and Welfare approved the molecularly defined indications based on data from the PAOLA-1, PROfound, and POLO trials.
With the PARIS test, researchers identified several targeted agents that could help patients overcome PARP inhibitor resistance and may be worth further study.
The study, presented at the NSGC annual conference last week, supports the broader use of panel testing for cancer patients suspected of hereditary disease.
The company has used its semi-closed electroporation system to manufacture autologous CAR T cells to treat ovarian cancer and leukemia patients in two trials.
